Combined effect of cabozantinib and gefitinib in crizotinib-resistant lung tumors harboring ROS1 fusions. [electronic resource]
Producer: 20181012Description: 3149-3158 p. digitalISSN:- 1349-7006
- Anilides -- pharmacology
- Animals
- Antigens, Differentiation, B-Lymphocyte -- genetics
- Antineoplastic Combined Chemotherapy Protocols -- pharmacology
- Carcinoma, Non-Small-Cell Lung -- drug therapy
- Cell Line, Tumor
- Crizotinib
- Drug Resistance, Neoplasm -- genetics
- ErbB Receptors -- metabolism
- Female
- Gefitinib
- Heparin-binding EGF-like Growth Factor -- metabolism
- Histocompatibility Antigens Class II -- genetics
- Humans
- Lung Neoplasms -- drug therapy
- Mice
- Mice, Inbred NOD
- Oncogene Proteins, Fusion -- genetics
- Protein Kinase Inhibitors -- pharmacology
- Protein-Tyrosine Kinases -- antagonists & inhibitors
- Proto-Oncogene Proteins -- antagonists & inhibitors
- Pyrazoles -- pharmacology
- Pyridines -- pharmacology
- Quinazolines -- pharmacology
- Receptor Protein-Tyrosine Kinases -- metabolism
- Sodium-Phosphate Cotransporter Proteins, Type IIb -- genetics
- Up-Regulation
- Xenograft Model Antitumor Assays
- Axl Receptor Tyrosine Kinase
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.